C WorldWide Group’s Coherus Oncology CHRS Stock Holding History

C WorldWide Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.26M	Hold	1,928,464	–	–	0.07%	75
2025 Q4	$2.74M	Hold	1,928,464	–	–	0.05%	79
2025 Q3	$3.16M	Hold	1,928,464	–	–	0.05%	77
2025 Q2	$1.41M	Hold	1,928,464	–	–	0.02%	87
2025 Q1	$1.56M	Hold	1,928,464	–	–	0.02%	83
2024 Q4	$2.66M	Hold	1,928,464	–	–	0.03%	71
2024 Q3	$2.01M	Hold	1,928,464	–	–	0.02%	77
2024 Q2	$3.34M	Hold	1,928,464	–	–	0.04%	71
2024 Q1	$4.61M	Hold	1,928,464	–	–	0.05%	66
2023 Q4	$6.42M	Hold	1,928,464	–	–	0.09%	65
2023 Q3	$7.21M	Hold	1,928,464	–	–	0.1%	63
2023 Q2	$8.23M	Buy	1,928,464 +1,000,000	+108%	+$5.9M	0.11%	64
2023 Q1	$6.35M	Hold	928,464	–	–	0.09%	64
2022 Q4	$7.35M	Hold	928,464	–	–	0.1%	49
2022 Q3	$8.92M	Hold	928,464	–	–	0.12%	46
2022 Q2	$6.72M	Hold	928,464	–	–	0.08%	53
2022 Q1	$12M	Hold	928,464	–	–	0.13%	42
2021 Q4	$14.8M	Hold	928,464	–	–	0.14%	40
2021 Q3	$14.9M	Sell	928,464 -130,000	-12%	-$1.91M	0.15%	38
2021 Q2	$14.6M	Hold	1,058,464	–	–	0.15%	42
2021 Q1	$15.5M	Hold	1,058,464	–	–	0.15%	47
2020 Q4	$18.4M	Hold	1,058,464	–	–	0.18%	46
2020 Q3	$19.4M	Buy	1,058,464 +150,000	+17%	+$2.79M	0.22%	38
2020 Q2	$16.2M	Hold	908,464	–	–	0.19%	42
2020 Q1	$14.7M	Buy	908,464 +100,000	+12%	+$1.85M	0.21%	36
2019 Q4	$14.6M	Hold	808,464	–	–	0.17%	40
2019 Q3	$16.4M	Buy	808,464 +130,000	+19%	+$2.6M	0.21%	30
2019 Q2	$15M	Buy	678,464 +480,000	+242%	+$8.34M	0.19%	37
2019 Q1	$2.71M	Buy	198,464 +27,939	+16%	+$373K	0.03%	80
2018 Q4	$1.54M	Sell	170,525 -57,371	-25%	-$664K	0.02%	89
2018 Q3	$3.76M	Sell	227,896 -39,261	-15%	-$696K	0.05%	74
2018 Q2	$3.74M	Buy	267,157 +93,942	+54%	+$1.34M	0.05%	78
2018 Q1	$1.91M	Sell	173,215 -26,639	-13%	-$291K	0.03%	82
2017 Q4	$1.76M	Sell	199,854 -39,117	-16%	-$419K	0.03%	93
2017 Q3	$3.19M	Sell	238,971 -2,534	-1%	-$33.5K	0.05%	77
2017 Q2	$3.47M	Buy	241,505 +48,618	+25%	+$935K	0.05%	75
2017 Q1	$4.08M	Buy	192,887 +98,211	+104%	+$2.42M	0.07%	62
2016 Q4	$2.67M	Sell	94,676 -62,124	-40%	-$1.74M	0.05%	72
2016 Q3	$4.2M	Buy	156,800 +5,800	+4%	+$158K	0.07%	58
2016 Q2	$2.55M	Buy	151,000 +2,500	+2%	+$46.9K	0.05%	66
2016 Q1	$3.15M	Buy	148,500 +2,500	+2%	+$41K	0.06%	57
2015 Q4	$3.35M	Buy	146,000 +22,000	+18%	+$566K	0.06%	66
2015 Q3	$2.48M	Buy	124,000 +64,000	+107%	+$1.95M	0.04%	78
2015 Q2	$1.73M	Buy	+60,000	New	+$1.52M	0.02%	92

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

C WorldWide Group's CHRS Position: Q1 2026 in Review

C WorldWide Group held its Coherus Oncology (CHRS) position steady in Q1 2026 at 1,928,464 shares worth $3.26M. The position accounts for 0.07% of the portfolio, ranked #75.

C WorldWide Group first reported a position in CHRS in Q2 2015 and has held it in 44 quarters since. The position peaked at $19.4M in Q3 2020. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

C WorldWide Group held 1,928,464 shares of Coherus Oncology worth $3.26M as of Q1 2026.
C WorldWide Group left its Coherus Oncology share count unchanged in Q1 2026.
Coherus Oncology made up 0.07% of C WorldWide Group's portfolio in Q1 2026, its #75 holding.
C WorldWide Group first reported a position in Coherus Oncology in Q2 2015 and has held it in 44 quarters since.
C WorldWide Group's Coherus Oncology position peaked at $19.4M in Q3 2020.
157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on C WorldWide Group's 13F filing for Q1 2026, filed 6 May 2026.